BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34162491)

  • 21. Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification.
    Abdollah F; Boorjian S; Cozzarini C; Suardi N; Sun M; Fiorino C; di Muzio N; Karakiewicz PI; Montorsi F; Karnes RJ; Briganti A
    Eur Urol; 2013 Oct; 64(4):557-64. PubMed ID: 23506833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
    Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
    Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
    Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
    Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram.
    Abdollah F; Klett DE; Sood A; Sammon JD; Pucheril D; Dalela D; Diaz M; Peabody JO; Trinh QD; Menon M
    BJU Int; 2015 Nov; 116(5):703-12. PubMed ID: 25413443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?
    Nguyen DP; Vertosick EA; Sharma V; Corradi RB; Vilaseca A; Takeda T; Sjoberg DD; Benfante N; Fine SW; Reuter VE; Scardino PT; Eastham JA; Karnes RJ; Touijer KA
    J Urol; 2018 Jun; 199(6):1502-1509. PubMed ID: 29307681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncological outcomes of pathologically organ-confined, lymph node-positive prostate cancer after radical prostatectomy.
    Stolzenbach LF; Knipper S; Mandel P; Ascalone L; Deuker M; Tian Z; Heinzer H; Tilki D; Maurer T; Graefen M; Karakiewicz PI; Steuber T
    Urol Oncol; 2021 Apr; 39(4):234.e1-234.e7. PubMed ID: 33097398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Prostate Cancer Stage Groups Updated in the 8th Edition of the American Joint Committee on Cancer Tumor-Node-Metastasis Staging Manual.
    Lee H; Lee M; Byun SS; Lee SE; Hong SK
    Clin Genitourin Cancer; 2019 Feb; 17(1):e221-e226. PubMed ID: 30472041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort.
    Tilki D; Mandel P; Schlomm T; Chun FK; Tennstedt P; Pehrke D; Haese A; Huland H; Graefen M; Salomon G
    J Urol; 2015 Jun; 193(6):1970-5. PubMed ID: 25498570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
    Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
    Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients.
    Xu H; Zhu Y; Dai B; Ye DW
    Asian J Androl; 2018; 20(6):551-554. PubMed ID: 30027928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage Radical Prostatectomy for Recurrent Prostate Cancer Following First-line Nonsurgical Treatment: Validation of the European Association of Urology Criteria in a Large, Multicenter, Contemporary Cohort.
    Calleris G; Marra G; Benfant N; Rajwa P; Ahmed M; Abreu A; Cacciamani G; Ghoreifi A; Ribeiro L; Westhofen T; Tourinho-Barbosa R; Raskin Y; Veerman H; Albisinni S; Smith JA; Rouprêt M; Oderda M; Massari E; Persad R; Van Der Poel H; Joniau S; Sanchez-Salas R; Kretschmer A; Cathcart P; Gill I; Karnes RJ; Tilki D; Shariat SF; Touijer K; Gontero P
    Eur Urol Focus; 2023 Jul; 9(4):645-649. PubMed ID: 36682962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
    Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
    Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline.
    Pompe RS; Karakiewicz PI; Tian Z; Mandel P; Steuber T; Schlomm T; Salomon G; Graefen M; Huland H; Tilki D
    J Urol; 2017 Aug; 198(2):354-361. PubMed ID: 28216329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
    Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer.
    Boehm K; Beyer B; Tennstedt P; Schiffmann J; Budaeus L; Haese A; Graefen M; Schlomm T; Heinzer H; Salomon G
    World J Urol; 2015 Jun; 33(6):801-6. PubMed ID: 24989847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.
    Chade DC; Shariat SF; Cronin AM; Savage CJ; Karnes RJ; Blute ML; Briganti A; Montorsi F; van der Poel HG; Van Poppel H; Joniau S; Godoy G; Hurtado-Coll A; Gleave ME; Dall'Oglio M; Srougi M; Scardino PT; Eastham JA
    Eur Urol; 2011 Aug; 60(2):205-10. PubMed ID: 21420229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.